Search results
Is Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) the Leading Gene Therapy Stock to Buy Now?
Insider Monkey via Yahoo Finance· 2 days agoWe recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we...
Eli Lilly Beefs Up Neuro Pipeline With Addition Of Preclinical ALS, Dementia Prospect
Benzinga· 2 days agoOn Monday, privately held QurAlis Corporation entered into an exclusive license agreement with Eli...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 5 days agoCENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today ...
Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a...
Morningstar· 6 days agoQALSODY is the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND).
Lilly gilds neuro pipeline, paying QurAlis $45M for preclinical ALS, dementia prospect
FierceBiotech· 3 days agoEli Lilly is splicing another asset onto its neurodegenerative disease pipeline, paying QurAlis $45 million for rights to a preclinical treatment for amyotrophic ...
The Unbreakable Spirit: A Caregiver's Testimony And Expert Guide For Supporting A Loved One |...
Essence· 14 hours agoDaryl Wynne was marked by this mantra from a young age. “I remember going out there as a kid and...
Alan Jackson's new tour dates give fans 'one final chance' to see him perform — what to know
AOL· 6 days agoAlan Jackson is hitting the road again for a "Last Call." The country music superstar, 65, announced May 30 on his official website that he's gearing up to resume his “Last Call: One More for ...
Lazy, burnt out or afflicted with the ‘sleepy gene’? I tried to find out why I sleep so much
The Telegraph via Yahoo News· 7 days agoThe first time I realised this could be a problem – and by problem, I mean an actual health concern...
New Clinical Assessment Tool Improves Dementia Care Actions in Primary Care Patients, NIH Reports
Sierra Sun Times· 13 hours agoResource tripled the odds of receiving dementia-related care within 90 days. June 5, 2024 – A...
GenSight Biologics Appoints William Monteith to its Board of Directors - Gensight Biologics...
Benzinga· 3 days agoGenSight Biologics (SIGHTGSGTF PEA-PME eligible)) SIGHT, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative